{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:00:23Z","timestamp":1793642423914,"version":"4.5.1"},"reference-count":69,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T00:00:00Z","timestamp":1713744000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca PLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013995","name":"Genzyme Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006259","name":"Teva Pharmaceutical Industries Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim Corp USA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.jaci.2024.03.023","type":"journal-article","created":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T02:56:55Z","timestamp":1713841015000},"page":"580-591.e6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"title":["Utility of eosinophil peroxidase as a biomarker of eosinophilic inflammation in asthma"],"prefix":"10.1016","volume":"154","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8847-5817","authenticated-orcid":false,"given":"Monica","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annabelle R.","family":"Charbit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mats W.","family":"Johansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nizar N.","family":"Jarjour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loren C.","family":"Denlinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilfred W.","family":"Raymond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleanor M.","family":"Dunican","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaharu","family":"Sumino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serpil C.","family":"Erzurum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzy A.","family":"Comhair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy C.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce D.","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elliot","family":"Israel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanda","family":"Phipatanakul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda R.","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David T.","family":"Mauger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene R.","family":"Bleecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally E.","family":"Wenzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merritt L.","family":"Fajt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prescott G.","family":"Woodruff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette T.","family":"Hastie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John V.","family":"Fahy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2024.03.023_bib1","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nri3786","article-title":"Type 2 inflammation in asthma\u2014present in most, absent in many","volume":"15","author":"Fahy","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jaci.2024.03.023_bib2","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1056\/NEJMra2032506","article-title":"Biologic therapies for severe asthma","volume":"386","author":"Brusselle","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2024.03.023_bib4","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1183\/09031936.00202013","article-title":"International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma","volume":"43","author":"Chung","year":"2014","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaci.2024.03.023_bib5","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S2213-2600(15)00419-1","article-title":"Blood or sputum eosinophils to guide asthma therapy?","volume":"3","author":"Mukherjee","year":"2015","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaci.2024.03.023_bib6","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/JLB.5MR0118-028R","article-title":"Revisiting the NIH Taskforce on the Research needs of Eosinophil-Associated Diseases (RE-TREAD)","volume":"104","author":"Khoury","year":"2018","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.jaci.2024.03.023_bib7","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jaci.2013.03.044","article-title":"Biomarker surrogates do not accurately predict sputum eosinophil and neutrophil percentages in asthmatic subjects","volume":"132","author":"Hastie","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2024.03.023_bib8","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1172\/JCI85664","article-title":"Lung-resident eosinophils represent a distinct regulatory eosinophil subset","volume":"126","author":"Mesnil","year":"2016","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaci.2024.03.023_bib9","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1016\/j.mayocp.2021.04.025","article-title":"Eosinophils in health and disease: a state-of-the-art review","volume":"96","author":"Wechsler","year":"2021","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jaci.2024.03.023_bib10","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1067\/mai.2000.105712","article-title":"Mechanisms of eosinophil-associated inflammation","volume":"105","author":"Gleich","year":"2000","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2024.03.023_bib11","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1111\/all.12206","article-title":"Eosinophil peroxidase in sputum represents a unique biomarker of airway eosinophilia","volume":"68","author":"Nair","year":"2013","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2024.03.023_bib12","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/978-1-0716-1001-5_17","article-title":"Assessment of lung eosinophils in situ using immunohistological staining","volume":"2223","author":"Nazaroff","year":"2021","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.jaci.2024.03.023_bib13","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/all.15481","article-title":"Urine eosinophil-derived neurotoxin: a potential marker of activity in select eosinophilic disorders","volume":"78","author":"Makiya","year":"2023","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2024.03.023_bib14","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/jlb.52.6.611","article-title":"Eosinophil granule proteins in peripheral blood granulocytes","volume":"52","author":"Abu-Ghazaleh","year":"1992","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.jaci.2024.03.023_bib15","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0954-6111(96)90243-7","article-title":"Eosinophil peroxidase: a new serum marker of atopy and bronchial hyper-responsiveness","volume":"90","author":"Bjornsson","year":"1996","journal-title":"Respir Med"},{"key":"10.1016\/j.jaci.2024.03.023_bib16","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1164\/ajrccm.155.2.9032177","article-title":"Granulocyte activation markers in induced sputum: comparison between chronic obstructive pulmonary disease, asthma, and normal subjects","volume":"155","author":"Keatings","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2024.03.023_bib17","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1183\/09031936.97.10020361","article-title":"Effect of a bed covering system in children with asthma and house dust mite hypersensitivity","volume":"10","author":"Frederick","year":"1997","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaci.2024.03.023_bib18","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/j.1398-9995.1997.tb01021.x","article-title":"Serum eosinophil peroxidase (EPO) levels in asthmatic patients","volume":"52","author":"Sanz","year":"1997","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2024.03.023_bib19","first-page":"27","article-title":"Eosinophil soluble protein levels, eosinophil peroxidase and eosinophil cationic protein in asthmatic patients","volume":"9","author":"Parra","year":"1999","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1016\/j.jaci.2024.03.023_bib20","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1046\/j.1365-2222.1999.00680.x","article-title":"Intracellular expression and serum levels of eosinophil peroxidase (EPO) and eosinophil cationic protein in asthmatic children","volume":"29","author":"Krug","year":"1999","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2024.03.023_bib21","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1034\/j.1399-3038.1999.101001.x","article-title":"Markers of inflammation and bronchial reactivity in children with asthma, exposed to animal dander in school dust","volume":"10","author":"L\u00f6nnkvist","year":"1999","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.jaci.2024.03.023_bib22","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1053\/rmed.2000.0970","article-title":"Granulocyte markers in induced sputum in patients with respiratory disorders and healthy persons obtained by two sputum-processing methods","volume":"95","author":"Metso","year":"2001","journal-title":"Respir Med"},{"key":"10.1016\/j.jaci.2024.03.023_bib23","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/S0891-5849(02)00976-0","article-title":"Eosinophil peroxidase produces hypobromous acid in the airways of stable asthmatics","volume":"33","author":"Aldridge","year":"2002","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.jaci.2024.03.023_bib24","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/all.12817","article-title":"Nasal and pharyngeal eosinophil peroxidase levels in adults with poorly controlled asthma correlate with sputum eosinophilia","volume":"71","author":"Rank","year":"2016","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2024.03.023_bib25","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.jaip.2017.05.032","article-title":"Baseline features of the Severe Asthma Research Program (SARP III) cohort: differences with age","volume":"6","author":"Teague","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2024.03.023_bib26","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1172\/JCI95693","article-title":"Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction","volume":"128","author":"Dunican","year":"2018","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaci.2024.03.023_bib27","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1164\/ajrccm\/147.5.1126","article-title":"Cellular and biochemical analysis of induced sputum from asthmatic and from healthy subjects","volume":"147","author":"Fahy","year":"1993","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.jaci.2024.03.023_bib28","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa2034975","article-title":"Tezepelumab in adults and adolescents with severe, uncontrolled asthma","volume":"384","author":"Menzies-Gow","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2024.03.023_bib29","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jim.2014.05.020","article-title":"Development of a suspension array assay in multiplex for the simultaneous measurement of serum levels of four eosinophil granule proteins","volume":"411","author":"Makiya","year":"2014","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.jaci.2024.03.023_bib30","series-title":"Defining, establishing, and verifying reference intervals in the clinical laboratory. Approved Guideline","year":"2008"},{"key":"10.1016\/j.jaci.2024.03.023_bib31","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1016\/j.jaip.2020.06.067","article-title":"Biomarkers of type 2 airway inflammation as predictors of loss of asthma control during step-down therapy for well-controlled disease: the Long-Acting Beta-Agonist Step-Down Study (LASST)","volume":"8","author":"Bose","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2024.03.023_bib32","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-26949-7","article-title":"A sputum bioassay for airway eosinophilia using an eosinophil peroxidase aptamer","volume":"12","author":"Ali","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.jaci.2024.03.023_bib33","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1155\/2007\/190618","article-title":"Sputum neutrophilia can mask eosinophilic bronchitis during exacerbations","volume":"14","author":"D\u2019silva","year":"2007","journal-title":"Can Respir J"},{"key":"10.1016\/j.jaci.2024.03.023_bib34","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1016\/j.jaci.2019.01.038","article-title":"Eosinophil peroxidase, GATA3, and T-bet as tissue biomarkers in chronic rhinosinusitis","volume":"143","author":"Lal","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2024.03.023_bib35","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/MPG.0000000000000740","article-title":"The value of an additional review for eosinophil quantification in esophageal biopsies","volume":"61","author":"Stucke","year":"2015","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jaci.2024.03.023_bib36","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1136\/thx.52.6.569","article-title":"\u201cUltimate activation\u201d of eosinophils in\u00a0vivo: lysis and release of clusters of free eosinophil granules (Cfegs)","volume":"52","author":"Persson","year":"1997","journal-title":"Thorax"},{"key":"10.1016\/j.jaci.2024.03.023_bib37","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1038\/nri.2017.95","article-title":"Functions of tissue-resident eosinophils","volume":"17","author":"Weller","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jaci.2024.03.023_bib38","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.5415\/apallergy.2021.11.e30","article-title":"Eosinophil-mediated inflammation in the absence of eosinophilia","volume":"11","author":"Miyabe","year":"2021","journal-title":"Asia Pac Allergy"},{"key":"10.1016\/j.jaci.2024.03.023_bib39","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.cgh.2009.03.022","article-title":"A novel histologic scoring system to evaluate mucosal biopsies from patients with eosinophilic esophagitis","volume":"7","author":"Protheroe","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jaci.2024.03.023_bib40","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0140-6736(82)91152-7","article-title":"Identification by immunofluorescence of eosinophil granule major basic protein in lung tissues of patients with bronchial asthma","volume":"2","author":"Filley","year":"1982","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2024.03.023_bib41","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1056\/NEJM198508013130502","article-title":"Dermal deposition of eosinophil-granule major basic protein in atopic dermatitis. Comparison with onchocerciasis","volume":"313","author":"Leiferman","year":"1985","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2024.03.023_bib42","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting \u03b22-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2024.03.023_bib43","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1179\/135100000101535771","article-title":"Role of eosinophil peroxidase in the origins of protein oxidation in asthma","volume":"5","author":"Mitra","year":"2000","journal-title":"Redox Rep"},{"key":"10.1016\/j.jaci.2024.03.023_bib44","doi-asserted-by":"crossref","first-page":"22118","DOI":"10.1074\/jbc.M116.750034","article-title":"Eosinophil peroxidase catalyzed protein carbamylation participates in asthma","volume":"291","author":"Wang","year":"2016","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jaci.2024.03.023_bib45","doi-asserted-by":"crossref","first-page":"L548","DOI":"10.1152\/ajplung.00141.2022","article-title":"Urinary total conjugated 3-bromotyrosine, asthma severity, and exacerbation risk","volume":"323","author":"Wang","year":"2022","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.jaci.2024.03.023_bib46","doi-asserted-by":"crossref","first-page":"5763","DOI":"10.4049\/jimmunol.166.9.5763","article-title":"Eosinophils are a major source of nitric oxide-derived oxidants in severe asthma: characterization of pathways available to eosinophils for generating reactive nitrogen species","volume":"166","author":"MacPherson","year":"2001","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2024.03.023_bib47","doi-asserted-by":"crossref","first-page":"11866","DOI":"10.1021\/bi011206v","article-title":"Peroxidases inhibit nitric oxide (NO) dependent bronchodilation: development of a model describing NO-peroxidase interactions","volume":"40","author":"Abu-Soud","year":"2001","journal-title":"Biochemistry"},{"key":"10.1016\/j.jaci.2024.03.023_bib48","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1164\/rccm.201606-1129OC","article-title":"Lung pathologies in a chronic inflammation mouse model are independent of eosinophil degranulation","volume":"195","author":"Jacobsen","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2024.03.023_bib49","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1038\/s41556-021-00762-2","article-title":"Eosinophil extracellular traps drive asthma progression through neuro-immune signals","volume":"23","author":"Lu","year":"2021","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.jaci.2024.03.023_bib50","doi-asserted-by":"crossref","first-page":"326","DOI":"10.3390\/biom10020326","article-title":"Reduced local response to corticosteroids in eosinophilic chronic rhinosinusitis with asthma","volume":"10","author":"Kobayashi","year":"2020","journal-title":"Biomolecules"},{"key":"10.1016\/j.jaci.2024.03.023_bib51","doi-asserted-by":"crossref","first-page":"787","DOI":"10.3390\/biomedicines9070787","article-title":"Omalizumab restores response to corticosteroids in patients with eosinophilic chronic rhinosinusitis and severe asthma","volume":"9","author":"Kobayashi","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.jaci.2024.03.023_bib53","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1164\/rccm.200206-525OC","article-title":"Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study","volume":"167","author":"Kips","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2024.03.023_bib54","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1056\/NEJMoa0808991","article-title":"Mepolizumab and exacerbations of refractory eosinophilic asthma","volume":"360","author":"Haldar","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2024.03.023_bib55","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1056\/NEJMoa0805435","article-title":"Mepolizumab for prednisone-dependent asthma with sputum eosinophilia","volume":"360","author":"Nair","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2024.03.023_bib56","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1164\/rccm.201103-0396OC","article-title":"Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study","volume":"184","author":"Castro","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2024.03.023_bib57","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial","volume":"380","author":"Pavord","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2024.03.023_bib58","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","article-title":"Oral glucocorticoid-sparing effect of benralizumab in severe asthma","volume":"376","author":"Nair","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2024.03.023_bib59","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1164\/rccm.201707-1323OC","article-title":"Weight-adjusted intravenous reslizumab in severe asthma with inadequate response to fixed-dose subcutaneous mepolizumab","volume":"197","author":"Mukherjee","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2024.03.023_bib60","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1016\/j.jaip.2018.04.014","article-title":"Low blood eosinophil counts are not always a reliable marker of clinical response to mepolizumab in severe asthma","volume":"6","author":"Ojanguren","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2024.03.023_bib61","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1111\/all.14135","article-title":"The importance of being not significant: blood eosinophils and clinical responses do not correlate in severe asthma patients treated with mepolizumab in real life","volume":"75","author":"Bagnasco","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2024.03.023_bib62","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1164\/rccm.200208-789OC","article-title":"Eosinophil\u2019s role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway","volume":"167","author":"Flood-Page","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2024.03.023_bib63","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1067\/mai.2003.1382","article-title":"Anti-IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics","volume":"111","author":"Menzies-Gow","year":"2003","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2024.03.023_bib64","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1111\/cea.12695","article-title":"Role of local eosinophilopoietic processes in the development of airway eosinophilia in prednisone-dependent severe asthma","volume":"46","author":"Sehmi","year":"2016","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2024.03.023_bib65","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1365-2222.2012.04065.x","article-title":"Anti-IL-5 attenuates activation and surface density of \u03b22-integrins on circulating eosinophils after segmental antigen challenge","volume":"43","author":"Johansson","year":"2013","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2024.03.023_bib66","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1164\/rccm.201611-2234OC","article-title":"Mepolizumab attenuates airway eosinophil numbers, but not their functional phenotype, in asthma","volume":"196","author":"Kelly","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2024.03.023_bib67","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/S0140-6736(22)01198-9","article-title":"Mepolizumab for urban children with exacerbation-prone eosinophilic asthma in the USA (MUPPITS-2): a randomised, double-blind, placebo-controlled, parallel-group trial","volume":"400","author":"Jackson","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2024.03.023_bib68","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.jaci.2022.10.028","article-title":"Eosinophil depletion with benralizumab is associated with attenuated mannitol airway hyperresponsiveness in severe uncontrolled eosinophilic asthma","volume":"151","author":"Chan","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2024.03.023_bib69","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/jlb.63.6.715","article-title":"Localization of eosinophil-derived neurotoxin and eosinophil cationic protein in neutrophilic leukocytes","volume":"63","author":"Sur","year":"1998","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.jaci.2024.03.023_bib70","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.jaci.2013.05.020","article-title":"Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia","volume":"132","author":"Laviolette","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2024.03.023_bib71","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/j.jaci.2018.01.008","article-title":"Benralizumab attenuates airway eosinophilia in prednisone-dependent asthma","volume":"141","author":"Sehmi","year":"2018","journal-title":"J Allergy Clin Immunol"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674924003658?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674924003658?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T00:45:57Z","timestamp":1725497157000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674924003658"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":69,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S0091674924003658"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2024.03.023","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Utility of eosinophil peroxidase as a biomarker of eosinophilic inflammation in asthma","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2024.03.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}